Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin N Rome

Showing results (51-60 of 139) with videos related to

Pageof 14
Sort By:
JAMA|January 3, 2023
Estimated Medicare Part B Savings From Inflationary RebatesAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
JAMA|August 15, 2023
Gauging the Value of Top-Selling Drugs in Medicare-ReplyAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
JAMA Dermatology|September 24, 2025
Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic DiseaseNikhita J Perry, John S Barbieri, Benjamin N Rome
Annals of Internal Medicine|April 18, 2022
Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?Hussain S Lalani, Aaron S Kesselheim, Benjamin N Rome
Neurology|April 6, 2026
Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in MedicareAayan N Patel, Aaron S Kesselheim, Benjamin N Rome
Annals of Internal Medicine|June 20, 2022
Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug CompanyHussain S Lalani, Aaron S Kesselheim, Benjamin N Rome
JAMA|June 15, 2021
Association of California's Prescription Drug Coupon Ban With Generic Drug UseBenjamin N Rome, Joshua J Gagne, Aaron S Kesselheim
JAMA|January 23, 2014
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012Benjamin N Rome, Daniel B Kramer, Aaron S Kesselheim
JAMA|July 29, 2020
Drug Prices, Rebates, and DiscountsBenjamin N Rome, William B Feldman, Aaron S Kesselheim
JAMA|February 3, 2025
Trends in Fills, Spending, and Prices of Doxepin for InsomniaChristopher L Cai, Aaron S Kesselheim, Benjamin N Rome
Pageof 14

Showing results (51-60 of 139) with videos related to

Sort By:
Pageof 14
JAMA|January 3, 2023
Estimated Medicare Part B Savings From Inflationary RebatesAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
JAMA|August 15, 2023
Gauging the Value of Top-Selling Drugs in Medicare-ReplyAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
JAMA Dermatology|September 24, 2025
Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic DiseaseNikhita J Perry, John S Barbieri, Benjamin N Rome
Annals of Internal Medicine|April 18, 2022
Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?Hussain S Lalani, Aaron S Kesselheim, Benjamin N Rome
Neurology|April 6, 2026
Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in MedicareAayan N Patel, Aaron S Kesselheim, Benjamin N Rome
Annals of Internal Medicine|June 20, 2022
Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug CompanyHussain S Lalani, Aaron S Kesselheim, Benjamin N Rome
JAMA|June 15, 2021
Association of California's Prescription Drug Coupon Ban With Generic Drug UseBenjamin N Rome, Joshua J Gagne, Aaron S Kesselheim
JAMA|January 23, 2014
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012Benjamin N Rome, Daniel B Kramer, Aaron S Kesselheim
JAMA|July 29, 2020
Drug Prices, Rebates, and DiscountsBenjamin N Rome, William B Feldman, Aaron S Kesselheim
JAMA|February 3, 2025
Trends in Fills, Spending, and Prices of Doxepin for InsomniaChristopher L Cai, Aaron S Kesselheim, Benjamin N Rome
Pageof 14